TIZIANA LIFE SCIENCES LTD
TLSANASDAQTrading Snapshot
- Day Range
- $0.89 – $0.96
- 52-Week Range
- $0.76 – $2.10
- Volume (shares)
- 250,576
- Avg Volume (shares)
- —
- Shares Outstanding
- 128.0M
- Next Earnings
- —
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-0.16
- Dividend Yield
- —
- Dilution (1yr)
- +10.9%
TIZIANA LIFE SCIENCES LTD
TLSA
StockOtter · stockotter.spaceAbout TIZIANA LIFE SCIENCES LTD
Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody under development for a range of conditions including Crohn's disease, graft versus host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Additionally, the company is progressing Milciclib (TZLS-201), a small molecule inhibitor that targets multiple cyclin-dependent, tropomycin receptor, and Src family kinases to suppress abnormal cell growth and cancer progression. Another significant asset is anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody intended to mitigate IL6-induced inflammation and treat COVID-19 patients. Founded in 1998, Tiziana Life Sciences is based in London, United Kingdom.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
Tiziana Management Team to Attend the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto
BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development cand
Tiziana completes dosing in Phase 2 Alzheimer's trial of intranasal foralumab
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the last patient has begun dosing in its Phase 2 trial of intranasal foralumab in early or mild Alzheimer's disease, with topline data expected in the first quarter of 2027.
Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer's Disease
BOSTON, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development cand
Tiziana Life Sciences seeks FDA orphan drug status for nasal MSA therapy
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has asked the US Food and Drug Administration to grant orphan drug designation to its intranasal foralumab for multiple system atrophy (MSA), a rare neurodegenerative disease with
Tiziana doses first three patients in ALS trial of nasal antibody foralumab
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the first three participants have received their first dose of intranasal foralumab in a Phase 2a trial in people living with amyotrophic lateral sclerosis (ALS). The Healey
Tiziana Life Sciences completes patient visits in Phase 2a MS drug trial
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said Monday the last patient has completed their final visit in the company's Phase 2a clinical trial evaluating intranasal foralumab in patients with non-active secondary progress